Harrow Health reaffirmed its full‑year 2025 revenue guidance of $270–$280 million, a level unchanged from the prior guidance issued in November 2025. The reaffirmation follows a Q3 2025 quarter that delivered $71.6 million in revenue, up 45% year‑over‑year, and earnings per share of $0.33, beating consensus estimates of $0.24 by $0.09. The beat reflects disciplined cost management and a favorable mix shift toward high‑margin products.
The quarter’s revenue miss of $2.1 million versus analysts’ $73.70 million expectations was driven by a 3.5% decline in the VEVYE segment, offset by a 12% increase in IHEEZO and a 9% rise in TRIESENCE. VEVYE’s revenue fell to $22.6 million from $23.3 million, while IHEEZO grew to $21.9 million from $19.5 million, and TRIESENCE reached $6.9 million from $6.3 million. The mix shift toward higher‑margin IHEEZO and TRIESENCE helped keep gross profit margin at 74.6%, supporting the EPS beat.
In addition to the quarterly results, Harrow announced a series of commercial expansion initiatives. The VEVYE sales force will double by Memorial Day, bringing the team to roughly 100 U.S. territories. IHEEZO will broaden its footprint into office‑based procedures, targeting an estimated 2.5 million annual procedures. TRIESENCE’s surgical sales force will also double, positioning the company to capture a larger share of the growing minimally invasive surgery market.
The company also reported progress toward filing a new drug application for its MELT‑300 sedation program, with the NDA expected in the first half of 2027. This follows the November 2025 acquisition of Melt Pharmaceuticals, which added the MELT‑210, MELT‑300, and MELT‑400 pipeline assets to Harrow’s portfolio.
Harrow’s ImprimisRx division resolved all pending regulatory matters with the California Board of Pharmacy and voluntarily exited the California market effective February 1, 2026, citing the state’s increasingly costly and unpredictable regulatory environment. The exit incurred an administrative fine of approximately $157,000 but is projected to have a material impact of less than 1% on consolidated operations.
CEO Mark L. Baum highlighted the company’s “OneHarrow” initiative, stating that consolidating all products under a single commercial organization will provide greater focus, tighter alignment, and a unified effort, driving disciplined and coordinated execution across a single organization. Investors reacted positively to the reaffirmation and the concrete commercial expansion plans, with trading volume high on the day of the announcement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.